Close Menu

NEW YORK – Sermonix Pharmaceuticals said on Wednesday that it has partnered with Exactis Innovation to expand a Phase II study of its investigational drug lasofoxifene into Canada.

The Phase II ELAINE-1 trial is comparing the activity of lasofoxifene versus fulvestrant in post-menopausal, estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer patients with ESR1 mutations. In the trial, which began enrollment in the US a year ago, researchers will compare patients' progression-free survival on these two agents.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.